A high-purity swertiamarin extract, its extraction and purification process, and its application.

By employing a process of low-temperature water precipitation and segmented elution with macroporous adsorption resin, the problems of impurity removal and heat sensitivity in the extraction of swertiamarin were solved, achieving efficient extraction of high-purity swertiamarin, which is suitable for industrial production and expands its medicinal applications.

CN123106786APending Publication Date: 2026-11-17CHENGDU SANUO LIANCHUANG BIOTECHNOLOGY CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611455292.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-18
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing technologies struggle to efficiently remove lipid-soluble impurities during the extraction of swertiamarin under mild conditions, making it difficult to balance product purity and yield. Furthermore, heat-sensitive components are prone to degradation during multi-step purification processes, making it impossible to achieve high-purity extraction in a single step.

Method used

The process employs low-temperature water precipitation and segmented elution with macroporous adsorption resin. By allowing the lipid-soluble impurities to settle under static conditions of 0~10℃, and then using 20%~30% ethanol for precise elution, heat-sensitive degradation is avoided, thus achieving the one-step extraction of high-purity swertiamarin.

Benefits of technology

It significantly improved the purity and yield of swertiamarin, reduced production costs and cycle time, expanded its application in hepatoprotective, anti-inflammatory, hypoglycemic and central nervous system protective drugs, and has good repeatability and industrial applicability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106786A_ABST
    Figure CN123106786A_ABST
Patent Text Reader

Abstract

This invention discloses a high-purity swertiamarin extract, its extraction and purification process, and its applications, belonging to the field of natural drug extraction technology. The process uses the whole herb of *Swertiamarin* as raw material. After extraction with ethanol under reflux and concentration under reduced pressure, lipid-soluble impurities are removed by low-temperature water precipitation at 0-10℃ for 8-24 hours. The supernatant is collected by centrifugation, concentrated, and then loaded onto a macroporous adsorption resin column. Elution is performed sequentially with pure water and 10%-40% ethanol aqueous solution. The target eluent is collected, concentrated, and dried to obtain the final product. This invention utilizes the synergistic effect of low-temperature water precipitation and precise elution to obtain a high-purity extract with swertiamarin content ≥90%, gentiopicrin ≤1.2%, and swertiamarin ≤0.8% in one step, without the need for silica gel column chromatography or recrystallization. The process is simple, reproducible, and suitable for industrial scale-up. The obtained product can be used to prepare anti-inflammatory, hepatoprotective, antioxidant, and type II diabetes, central nervous system protective drugs, and health supplements.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This application relates to the field of natural drug extraction, and more specifically, to a high-purity Swertia japonica glycoside extract, its extraction and purification process, and its application. Background Technology

[0002] Swertiamarin is the main active iridoid glycoside found in plants of the genus *Swertia* (specifically, *Swertia pseudochinensis* Hara) in the Gentianaceae family. It possesses a variety of pharmacological activities, including hepatoprotective, anti-inflammatory, choleretic, and antioxidant effects, making it an important monomeric raw material for the development of hepatoprotective drugs, anti-inflammatory agents, and functional health products. With the rapid development of the natural medicine market, the market demand for high-purity (≥90%) swertiamarin is increasing, placing comprehensive requirements on its industrial preparation process in terms of purity, yield, and cost.

[0003] Currently, the conventional process for extracting and purifying high-purity swertiamarin from Swertia species generally employs a multi-step purification method involving "ethanol extraction + macroporous resin crude enrichment + silica gel column chromatography purification + recrystallization." This type of process has the following prominent problems in actual production: First, incomplete removal of lipid-soluble impurities forces subsequent purification processes to be layered upon each other. After ethanol extraction of the whole herb, the extract contains a large amount of lipid-soluble impurities such as chlorophyll, oils, resins, and waxes. These impurities have limited polarity differences from swertiamarin, making them difficult to separate effectively using conventional ethanol extraction and water precipitation or direct loading onto macroporous resins. Existing water precipitation processes are mostly carried out at room temperature (approximately 25°C), or with only brief stirring followed by centrifugation. This results in insufficient sedimentation of lipid-soluble impurities, leaving a large amount remaining in the sample solution, directly contaminating the macroporous resin pores and reducing the resin's selective adsorption capacity. Once the resin is contaminated by lipid-soluble impurities, its subsequent elution and separation efficiency deteriorates significantly, and the product purity cannot reach the requirement of over 90%. Further purification steps, such as silica gel column chromatography and recrystallization, must be added. Each additional purification step is accompanied by increased material transfer losses, increased organic solvent consumption, and extended production cycles, creating a vicious cycle of "incomplete coarse separation and repeated remedial purification."

[0004] Secondly, the thermosensitivity of swertiamarin is severely overlooked in multi-step processes. Swertiarin belongs to the iridoid glycoside class of compounds, and its hemiacetal ketal lactone ring is extremely sensitive to heat and hydrolysis. During multi-step purification, the material repeatedly undergoes heating and concentration, prolonged room-temperature column chromatography, and contact with organic solvents, making swertiamarin highly susceptible to ring-opening hydrolysis and structural degradation. Especially when the process relies on silica gel column chromatography, the weakly acidic environment of silica gel further accelerates the hydrolysis of iridoid glycosides. This results in a significant decrease in actual yield even with a high swertiamarin content in the raw material after multi-stage purification, creating a clear trade-off between product purity and yield—pursuing high purity leads to a sharp drop in yield, while pursuing high yield results in insufficient purity.

[0005] Meanwhile, there is a common perception among those skilled in the art that macroporous adsorption resins are only suitable as a crude enrichment method, and that single-resin fractional elution cannot obtain swertiamarin products with a purity of over 90%, requiring further purification by silica gel column chromatography or recrystallization. Guided by this technical bias, existing improvement schemes mostly focus on simple resin replacement or broad adjustments to elution concentrations, neglecting a crucial issue—the thorough removal of lipid-soluble impurities is the decisive factor in whether macroporous resins can independently achieve deep purification. Conventional room-temperature water precipitation is limited by temperature conditions, failing to allow lipid-soluble impurities (especially chlorophyll and waxes) to fully coagulate and precipitate, thus this problem has remained unresolved.

[0006] Therefore, there is an urgent need in this field for an extraction and purification process that can efficiently remove fat-soluble impurities under mild conditions, avoid degradation of heat-sensitive components, and obtain high-purity swertiamarin in one step without the need for multiple refining steps, so as to achieve a comprehensive improvement in purity, yield and industrial feasibility. Summary of the Invention

[0007] To address the aforementioned issues, this application provides a high-purity swertiamarin extract, its extraction and purification process, and its applications. This process, through optimized alcohol extraction parameters, low-temperature water precipitation for impurity removal, and segmented resin elution conditions, maximizes the retention of the active components of swertiamarin while efficiently removing lipid-soluble and water-soluble impurities, significantly improving product purity and yield. Furthermore, it includes comprehensive content limits for multiple components in the extract, expanding its application in compound formulations, hypoglycemic agents, and neuroprotective agents. The process is stable, controllable, and suitable for large-scale industrial production.

[0008] The technical solution adopted in this application is as follows: In a first aspect, this application provides a process for extracting and purifying high-purity swertiamarin, comprising: S1. Take the dried whole medicinal herb, roughly cut it into segments, add 55%~85% ethanol aqueous solution by volume, heat and reflux to extract 2~3 times, combine the extracts and filter, concentrate the filtrate under reduced pressure at 45~60℃ to an alcohol extract with a relative density of 1.0~1.1 at 50℃; S2. Add purified water to the alcohol extract to dilute and stir evenly. Let it stand at 0~10℃ for 8~24h to allow fat-soluble impurities to settle. Then centrifuge for 8~15min, collect the supernatant and concentrate under reduced pressure. S3. The obtained concentrated solution is loaded onto a macroporous adsorption resin column. The macroporous adsorption resin is a non-polar macroporous adsorption resin. The loading flow rate is 0.5~2 BV / h. After loading, it is eluted with 1~5 BV of pure water and then with 2~8 BV of 10%~40% ethanol aqueous solution. The target eluent is collected, concentrated under reduced pressure at 40~55℃, and then dried under low temperature vacuum to obtain Swertia japonica extract. The extract contains ≥90% swertiamarin, ≤1.2% gentiopicrin, and ≤0.8% gentiopicrin.

[0009] Further, in step S1, the material-to-liquid ratio for the heating and reflux extraction is 1g:8~15mL, and the extraction time is 1~2h each time.

[0010] Further, in step S2, the mass ratio of the alcohol extract to purified water is 1:2~6.

[0011] Further, in step S1, the volume fraction of the ethanol aqueous solution is 60%~80%, and the relative density of the alcohol extract measured at 50°C is 1.0~1.03.

[0012] Further, in step S3, the macroporous adsorption resin is selected from any one of D101, AB-8, or LX-183S.

[0013] Further, in step S3, the sample loading flow rate is 0.5 BV / h, the elution volume of pure water is 2~4 BV, the volume fraction of the target eluent is 20%~30%, and the elution volume is 2~6 BV.

[0014] Furthermore, in step S1, the heating and reflux extraction is performed 3 times, with each extraction lasting 1 hour.

[0015] Secondly, this application provides a high-purity swertiamarin extract, prepared by the above-mentioned extraction and purification process.

[0016] Furthermore, the extract contains ≥90% swertiamarin, ≤1.2% gentiopicrin, ≤0.8% gentiopicrin, and <0.5% total fat-soluble impurities.

[0017] Thirdly, this application provides the application of the above-mentioned high-purity swertiamarin extract in the preparation of drugs for treating type II diabetes, anti-anxiety, and antidepressant diseases.

[0018] In summary, this application has the following beneficial effects: 1. This invention employs a low-temperature water precipitation process (0-10℃) to allow lipid-soluble impurities such as chlorophyll, oils, resins, and waxes to fully coagulate and settle under low-temperature conditions, which are then effectively removed by centrifugation. Comparative experiments show that low-temperature water precipitation significantly improves product purity and total yield compared to room-temperature water precipitation or no water precipitation treatment, while greatly reducing the frequency of resin contamination, extending the continuous use of resin batches, and reducing regeneration and maintenance costs.

[0019] 2. Through systematic screening, the inventors discovered that when the ethanol concentration is below 20%, the elution of swertiamarin is incomplete and the recovery rate is low. When the concentration is above 30%, a large amount of medium polar glycosides and pigments are eluted simultaneously, resulting in a decrease in purity. Only within the narrow range of 20% to 30% can the industrial requirements of high purity and high recovery rate be met simultaneously. Among these, the amount of impurities co-soluble is the least and the balance between purity and yield is optimal when eluted with 20% to 30% ethanol.

[0020] 3. There is a common technical bias in the field that "macroporous resins are only suitable for crude enrichment," believing that silica gel column chromatography or recrystallization must be added to obtain high-purity swertiamarin. This invention unexpectedly demonstrates that the feed solution, after deep removal of lipid-soluble impurities by low-temperature water precipitation, combined with precise fractional elution with 20%~30% ethanol, can achieve deep purification from crude extract to high-purity product in a single step using only macroporous adsorption resin, without any subsequent refining processes. This technical effect is not a simple superposition of two conventional unit operations, but rather a synergistic result formed by the pre-removal of impurities allowing the resin adsorption selectivity to be fully utilized, and precise elution further amplifying the purity advantage, resulting in unexpected technical effects.

[0021] 4. Swertia triterpenoids are iridoid glycosides, and the hemiacetal-ketal lactone ring in their molecular structure is extremely sensitive to heat and hydrolysis. This invention reduces the risks of repeated heating, prolonged contact with organic solvents, and ring-opening hydrolysis under the weakly acidic environment of silica gel by omitting silica gel column chromatography and recrystallization. The entire process utilizes a low-to-medium temperature treatment system and avoids the use of strong acids and bases. Compared to traditional processes that rely on multi-step purification, the overall yield is significantly improved, the production cycle is greatly shortened, and the consumption of organic solvents is significantly reduced.

[0022] 5. All process parameters involved in this invention have clearly defined ranges and optimal values, allowing for the stable acquisition of high-purity products without relying on operator experience. Comparative verification results of different resin types show that, under the defined process conditions, various non-polar macroporous adsorption resins can meet production requirements, providing flexibility for industrial equipment selection. The batch-to-batch data of each embodiment exhibit good consistency, demonstrating the stable repeatability and scalability of the process.

[0023] 6. The high-purity Swertia japonica extract prepared by this invention retains the original anti-inflammatory, hepatoprotective, antioxidant, and choleretic activities, and adds two new indications: hypoglycemic and central nervous system protection for type II diabetes, and anti-anxiety / depression. The high-purity product can effectively inhibit α-glucosidase activity, reduce intestinal sugar absorption, regulate 5-hydroxytryptamine neurotransmitter levels, and reduce oxidative stress damage to brain tissue. Impurities can directly interfere with or antagonize the above-mentioned efficacy, and low-purity extracts cannot achieve the expected effects. Only the high-purity product obtained by this invention possesses these medicinal activities.

[0024] 7. This invention constructs a complete in vivo animal and in vitro cell-based dual-layer pharmacodynamic evaluation system: the classic CCl4 rat liver injury model is used to verify the overall organ protection effect, and the LPS-induced macrophage inflammation model is used to elucidate the cellular level anti-inflammatory mechanism. Both sets of pharmacodynamic experiments jointly demonstrate that high purity is the core condition for ensuring the stable efficacy of swertiamarin. The low-purity crude product containing a large number of impurities and lipid-soluble impurities has significantly reduced hepatoprotective and anti-inflammatory activities, fully demonstrating the unique pharmaceutical development advantages of this process in preparing high-purity products, and expanding the application prospects of the product in the fields of hepatoprotective and anti-inflammatory drugs and functional health products. Attached Figure Description

[0025] Figure 1 This is a flowchart of the extraction and purification process of high-purity swertiamarin provided in this application; Figure 2 This is the HPLC chromatogram of high-purity swertiamarin provided in this application; Figure 3 This is a bar chart showing the relative activity of serum ALT (A) and AST (B) in rats from different experimental groups; Figure 4 This is a bar chart showing the relative contents of TNF-α (A) and IL-6 (B) in the supernatant of RAW264.7 cells from different experimental groups. Detailed Implementation

[0026] The embodiments of the present invention will be described in detail below with reference to the examples. However, those skilled in the art will understand that the following examples are only for illustrating the present invention and should not be regarded as limiting the scope of the present invention. Specific conditions not specified in the examples shall be carried out according to conventional conditions or conditions recommended by the manufacturer. Reagents or instruments whose manufacturers are not specified are all conventional products that can be purchased commercially.

[0027] 1. Raw medicinal materials: The raw material used in this invention is *Swertia spp.*, scientifically known as *Swertia spp.* Swertia pseudochinensis Hara *Swertia* is an annual herb belonging to the genus *Swertia* of the family Gentianaceae. It is widely distributed in Northeast, North, and Northwest my country. The whole plant is harvested in autumn, dried, and used medicinally. As a traditional Chinese medicine, it has the effects of clearing heat and dampness, strengthening the stomach and aiding digestion. Its main active ingredients are iridoid glycosides.

[0028] Swertiamarin (C 16 H 22 O 10 It has the highest content of ) and is accompanied by gentiopicroside (C 16 H 20 O9) and Sweroside (C 16 H 20 O9) and other structural analogs. Swertia triterpenoids are white or off-white crystalline powders, readily soluble in water, methanol, and ethanol. The hemiacetal-ketal lactone ring in its molecular structure is sensitive to heat and acids / bases, and readily undergoes ring-opening hydrolysis under heating or weakly acidic conditions. This invention strictly controls the processing temperature throughout the extraction and purification process (concentration 45-60℃, drying 40-55℃, water precipitation 0-10℃), and avoids the use of strong acid and base reagents to maximize the preservation of the structural integrity of this active ingredient.

[0029] 1. Chromatographic conditions: In all embodiments, comparative examples, and experimental examples of this invention, the content of swertiamarin and related impurities was detected using high-performance liquid chromatography (HPLC), with the specific chromatographic conditions as follows: Chromatographic column: C18 reversed-phase column (4.6 mm × 250 mm, 5 μm); Mobile phase: methanol (A) - 0.05% phosphoric acid aqueous solution (B), gradient elution: phase A: phase B = 22:78, isogradient elution for 35 min; Detection wavelength: 238 nm; flow rate: 1.0 mL / min; column temperature: 18 ℃; injection volume: 10 μL.

[0030] Reference standards: a mixed reference solution of swertiamarin, gentiopicrin, and strychnine.

[0031] Under the above chromatographic conditions, the retention time of the swertiamarin main peak in the sample chromatogram was 18.1~19.0 min. Gentianoside, gentianoside, and swertiamarin main peaks achieved baseline separation, with a resolution R > 1.5 for each component. The theoretical plate number, calculated based on the swertiamarin peak, was not less than 3000, and the peak shape was well-symmetrical. These HPLC detection conditions can be used for the simultaneous quantitative analysis of the main component and two major associated glycosides in the extract of this invention. Simultaneously, it allows for direct observation of residual lipid-soluble impurities (if present, they will appear as broad peaks at the beginning of the chromatogram), serving as a dedicated detection basis for product quality control.

[0032] The following provides a detailed description of specific embodiments of the present invention. It should be understood that the specific embodiments described herein are for illustrative and explanatory purposes only and are not intended to limit the scope of the invention.

[0033] Example 1 This embodiment provides a high-purity swertiamarin extraction and purification process, the process is as follows: Figure 1 As shown, it includes the following steps: S1. Take 100g of the dried whole herb of *Swertia serratifolia* (also known as hairy swert). S2. Add 1000 mL of 70% ethanol aqueous solution (material-liquid ratio 1g:10mL) to the above-mentioned medicinal materials, reflux and extract 3 times, 1 hour each time, combine the three extracts, and filter to remove the residue. S3. The combined extract was subjected to reduced pressure at 50°C to recover ethanol, and concentrated to an alcohol extract with a relative density of 1.03 at 50°C. S4. Add purified water to the obtained alcohol extract to make the mass ratio of extract to purified water 1:4. After stirring thoroughly, place it in a refrigerated environment at 4°C for 24 hours to allow the fat-soluble impurities to settle completely. S5. Centrifuge the water-precipitated mixture at 3500 r / min for 10 min, collect the supernatant, and discard the oily sludge precipitate at the bottom. S6. Concentrate the supernatant under reduced pressure at 50°C to about 1 / 3 to 1 / 5 of its original volume to obtain concentrated sample solution; S7. Load the concentrated sample solution into the pretreated LX-183S macroporous adsorption resin column at a flow rate of 0.5 BV / h. After the sample is loaded, use 4 BV of pure water to remove strong polar impurities such as polysaccharides, and then use 4 BV of 25% ethanol to elute the target component. Collect the ethanol eluent. S8. The target eluent was concentrated under reduced pressure at 50°C and then dried under low temperature vacuum to obtain Swertia triterpenoid extract.

[0034] HPLC analysis (results as follows) Figure 2As shown in the figure, the purity of swertiamarin in the extract obtained in this embodiment is 92.63%, the content of gentiopicrin is 0.75%, the content of gentiopicrin is 0.42%, the total fat-soluble impurities are 0.31%, and the total yield is 90.41%. The product is an off-white powder with no obvious oily impurities, and the resin shows no obvious contamination after multiple batches of continuous use.

[0035] Example 2 This embodiment provides a high-purity swertiamarin extraction and purification process, including the following steps: S1. Take 100g of dried Swertia japonica (the whole plant of the herb), and roughly cut it into sections; S2. Add 1000 mL of 85% ethanol aqueous solution (material-liquid ratio 1 g: 10 mL) to the above-mentioned medicinal materials, heat and reflux to extract 3 times, 1 hour each time, combine the three extracts, filter to remove the residue, and collect the extract. S3. The combined extract was subjected to reduced pressure at 50°C to recover ethanol, and the extract was concentrated to a relative density of 1.0~1.1 at 50°C. S4. Add purified water to the obtained alcohol extract to make the mass ratio of extract to purified water 1:4. After stirring thoroughly, place it in a refrigerated environment at 4°C for 24 hours to allow fat-soluble impurities to settle. S5. Centrifuge the water-precipitated mixture at 3500 r / min for 15 min, collect the supernatant and discard the bottom precipitate; S6. Concentrate the supernatant under reduced pressure at 50°C to about 1 / 3 to 1 / 5 of its original volume to obtain concentrated sample solution; S7. Load the concentrated sample solution into the pretreated AB-8 macroporous adsorption resin column at a flow rate of 0.8 BV / h. After the sample is loaded, use 2 BV of pure water to remove strong polar impurities such as polysaccharides, and then use 4 BV of 20% ethanol to elute the target component. Collect the ethanol eluent. S8. The target eluent was concentrated under reduced pressure at 50°C and then dried under low temperature vacuum to obtain Swertia triterpenoid extract.

[0036] According to HPLC analysis, the purity of swertiamarin in the extract obtained in this example was 90.24%, the content of gentiopicrin was 0.91%, the content of gentiopicrin was 0.55%, and the content of total lipid-soluble impurities was 0.38%.

[0037] Example 3 The difference between this embodiment and Embodiment 1 is that: In step S2, 800 mL of 55% ethanol aqueous solution (material-to-liquid ratio 1 g:8 mL) was added, and the mixture was refluxed twice, 1 h each time. In step S3, the reduced pressure concentration temperature was 45°C. In step S6, the mixture was concentrated to approximately 1 / 4 of its original volume. In step S7, the macroporous adsorption resin was D101, the loading flow rate was 1 BV / h, the elution volume of pure water was 2 BV, and elution was performed using 30% ethanol with a elution volume of 3 BV. The parameters for the remaining steps were the same as in Example 1.

[0038] According to HPLC analysis, the purity of swertiamarin in the extract obtained in this example was 90.56%, the content of gentiopicrin was 0.98%, the content of gentiopicrin was 0.61%, and the content of total lipid-soluble impurities was 0.35%.

[0039] Example 4 The difference between this embodiment and Example 1 is as follows: In step S2, 1500 mL of 75% ethanol aqueous solution (material-to-liquid ratio 1 g:15 mL) is added, and the mixture is refluxed three times, each time for 1.5 h; in step S3, the vacuum concentration temperature is 60℃, and the relative density of the ethanol extract is 1.0; in step S4, the mass ratio of ethanol extract to purified water is 1:6, the settling temperature is 10℃, and the settling time is 8 h; in step S5, the centrifugation speed is 4000 r / min, and the centrifugation time is 15 min; in step S6, the mixture is concentrated to approximately 1 / 5 of its original volume; in step S7, the macroporous adsorption resin is D101, the loading flow rate is 2 BV / h, the elution volume of pure water is 1 BV, and elution is performed using 20% ​​ethanol with a elution volume of 2 BV; in step S8, the concentration and drying temperature is 55℃. The remaining parameters are the same as in Example 1.

[0040] According to HPLC analysis, the purity of swertiamarin in the extract obtained in this example was 90.18%, the content of gentiopicrin was 1.05%, the content of gentiopicrin was 0.69%, and the content of total lipid-soluble impurities was 0.42%.

[0041] Example 5 The difference between this embodiment and Example 1 is as follows: In step S2, 1200 mL of 60% ethanol aqueous solution (material-to-liquid ratio 1 g:12 mL) is added, and the mixture is refluxed twice, each time for 1.5 h; in step S3, the relative density of the ethanol extract is 1.1; in step S4, the mass ratio of ethanol extract to purified water is 1:2, and the settling temperature is 0°C; in step S5, the centrifugation speed is 3000 r / min, and the centrifugation time is 8 min; in step S6, the mixture is concentrated to approximately 1 / 5 of its original volume; in step S7, 1 BV of pure water is used for elution, and 6 BV of 30% ethanol is used for elution; in step S8, the concentration and drying temperature is 45°C. The remaining parameters are the same as in Example 1.

[0042] According to HPLC analysis, the purity of swertiamarin in the extract obtained in this example was 91.35%, the content of gentiopicrin was 0.82%, the content of gentiopicrin was 0.53%, and the content of total lipid-soluble impurities was 0.29%.

[0043] Example 6 The difference between this embodiment and Example 1 is as follows: In step S2, reflux extraction is performed three times, each time for 2 hours; in step S6, the reduced pressure concentration temperature is 40°C, and the volume is concentrated to approximately 1 / 3 of the original volume; in step S7, the loading flow rate is 1 BV / h, the elution volume of pure water is 3 BV, and elution is performed using 30% ethanol (volume fraction) with a elution volume of 6 BV; in step S8, the concentration and drying temperature is 40°C. The remaining parameters are the same as in Example 1.

[0044] According to HPLC analysis, the purity of swertiamarin in the extract obtained in this example was 90.42%, the content of gentiopicrin was 1.08%, the content of gentiopicrin was 0.64%, and the content of total lipid-soluble impurities was 0.36%.

[0045] Example 7 The difference between this embodiment and Example 1 is as follows: In step S2, 800 mL of 70% ethanol aqueous solution (material-to-liquid ratio 1 g: 8 mL) is added, and reflux extraction is performed three times, 2 hours each time; in step S3, the vacuum concentration temperature is 60℃, and the relative density of the ethanol extract is 1.04; in step S4, the mass ratio of ethanol extract to purified water is 1:3, the settling temperature is 6℃, and the settling time is 12 hours; in step S5, the centrifugation speed is 3200 r / min, and the centrifugation time is 12 minutes; in step S6, the volume is concentrated to approximately 1 / 4 of the original volume, and the vacuum concentration temperature is 55℃; in step S7, the macroporous adsorption resin is AB-8, the loading flow rate is 1.5 BV / h, the elution volume of pure water is 3 BV, and elution is performed using 25% ethanol with a elution volume of 4 BV; in step S8, the concentration and drying temperature is 55℃. The remaining steps and parameters are the same as in Example 1.

[0046] According to HPLC analysis, the purity of swertiamarin in the extract obtained in this example was 90.87%, the content of gentiopicrin was 0.95%, the content of gentiopicrin was 0.58%, and the content of total lipid-soluble impurities was 0.33%.

[0047] Example 8 The difference between this embodiment and Example 1 is as follows: In step S2, 800 mL of 75% ethanol aqueous solution (material-to-liquid ratio 1 g: 8 mL) is added, and the mixture is refluxed twice, 2 h each time; in step S3, the vacuum concentration temperature is 55℃, and the relative density of the ethanol extract is 1.04; in step S4, the mass ratio of ethanol extract to purified water is 1:3, the settling temperature is 8℃, and the settling time is 16 h; in step S5, the centrifugation speed is 3800 r / min, and the centrifugation time is 9 min; in step S6, the mixture is concentrated to approximately 1 / 5 of its original volume, and the vacuum concentration temperature is 55℃; in step S7, the macroporous adsorption resin is D101, the loading flow rate is 1.5 BV / h, the elution volume of pure water is 3 BV, and elution is performed using 20% ​​ethanol with a elution volume of 3 BV; in step S8, the concentration and drying temperature is 40℃. The remaining steps and parameters are the same as in Example 1.

[0048] According to HPLC analysis, the purity of swertiamarin in the extract obtained in this example was 90.05%, the content of gentiopicrin was 1.12%, the content of gentiopicrin was 0.72%, and the content of total lipid-soluble impurities was 0.45%.

[0049] Performance testing Experiment Example 1: Comparative Experiment of Different Water Sedimentation Pretreatment Conditions This experiment aims to investigate the effects of three pretreatment conditions—low-temperature water precipitation, room-temperature water precipitation, and no water precipitation—on the extraction and purification of swertiamarin, and to verify the technical necessity of low-temperature water precipitation at 0~10℃.

[0050] 1. Experimental Methods Take 100g of dried whole herb of *Swertia marcescens* (also known as hairy swert), and extract them separately using the same alcohol extraction process: add 1000mL of 70% ethanol aqueous solution (material-to-liquid ratio 1g:10mL), reflux extraction 3 times, 1h each time, combine the extracts and filter. Concentrate the combined extract under reduced pressure at 50℃ to obtain an alcohol extract with a relative density of 1.03~1.04 at 50℃.

[0051] The obtained alcohol extracts were each added to purified water to make the mass ratio of extract to purified water 1:4. After thorough mixing, the mixture was divided into three groups and subjected to the following treatments: (1) Experimental group: Refrigerate at 4℃ for 24h, then centrifuge at 3500r / min for 10min and collect the supernatant. (2) Comparative Example 1 (room temperature water precipitation): Placed at room temperature of 25℃ for 24h, then centrifuged at 3500r / min for 10min, and the supernatant was collected; (3) Comparative Example 2 (no water sedimentation): After dilution and stirring, no static sedimentation was performed. Instead, the mixture was centrifuged at 3500 r / min for 10 min and the supernatant was collected.

[0052] The three groups of centrifuged supernatants underwent identical subsequent processing: they were concentrated under reduced pressure at 50°C to approximately 1 / 3 to 1 / 5 of their original volume, loaded onto a pretreated LX-183S macroporous adsorption resin column at a flow rate of 0.5 BV / h, and eluted sequentially with 4 BV of pure water and 4 BV of 25% (v / v) ethanol aqueous solution. The 25% ethanol eluent was collected, concentrated under reduced pressure at 50°C, and then dried under low-temperature vacuum. The purity and total yield of swertiamarin were determined by HPLC.

[0053] 2. Experimental Results Table 1. Comparison of three groups: no water sedimentation, water sedimentation at room temperature, and water sedimentation at 4℃. As can be seen from Table 1: (1) Without water precipitation treatment, a large number of fat-soluble impurities enter the resin column with the supernatant, resulting in a product purity of only 73.50% and rapid resin contamination, which cannot meet the requirements for high purity production. (2) Room temperature water precipitation can remove some fat-soluble impurities and increase the purity of the product to 82.17%, but it still cannot reach the purity standard of more than 90%. The resin contamination frequency is high, and further purification is still required to meet the standard. (3) Under the low temperature water precipitation condition of 4℃, chlorophyll, wax, resin and other fat-soluble impurities fully aggregate and settle. At the same time, the low temperature environment effectively inhibits the hydrolysis and degradation of heat-sensitive iridoid glycosides. The purity of the product jumps to 92.63%, the total yield reaches 90.41%, and the resin remains clean even after 8 to 10 consecutive batches. (4) There is a strong synergistic effect between low temperature water precipitation at 0~10℃ and subsequent macroporous resin purification: the pre-deep removal of lipid-soluble impurities avoids resin pore blockage, so that the resin only needs to separate the target glycosides and polysaccharide impurities with different polarities. A single resin can achieve the target in one step, rather than a simple superposition of two conventional separation methods.

[0054] Experimental Example 2: Screening of Elution Conditions for Different Concentrations of Ethanol This experiment aims to examine the rationality of the 20%~30% ethanol elution window and verify that this narrow concentration range is the optimal choice for balancing purity and yield.

[0055] 1. Experimental Methods Take 100g of dried whole herb of *Swertia marcescens* (also known as hairy swertia), and use the same alcohol extraction, concentration, and low-temperature water precipitation process as in Experiment 1: add 1000mL of 70% ethanol aqueous solution, reflux and extract 3 times, 1h each time; concentrate the extract under reduced pressure at 50℃ to a relative density of 1.0~1.1; add purified water to the alcohol extract at a mass ratio of 1:4, let stand at 4℃ for 24h, centrifuge at 3500r / min for 10min, collect the supernatant and concentrate.

[0056] The obtained concentrate was loaded onto five pretreated LX-183S macroporous adsorption resin columns at a flow rate of 0.5 BV / h. Each column was eluted sequentially with 4 BV of pure water, followed by elution with 4 BV of each of 5%, 10%, 20%, 30%, 40%, and 45% ethanol aqueous solutions. The ethanol eluents of the corresponding concentrations were collected, concentrated under reduced pressure at 50℃, and then dried under low-temperature vacuum. The purity and elution recovery rate of swertiamarin in each group were determined.

[0057] 2. Experimental Results Table 2 Elution effect of different ethanol concentration gradients As can be seen from Table 2: When the ethanol concentration is below 10%, the binding force between swertiamarin and macroporous adsorption resin is not sufficiently destroyed, resulting in incomplete elution of the target component and a recovery rate of less than 60%. This leads to excessive raw material loss in industrial production and renders the product impractical. When the ethanol concentration is above 40%, impurities such as neutral glycosides and pigments dissolve simultaneously, making it impossible to maintain a product purity consistently above 90%. The purity drops sharply to 76.46% when eluted with 45% ethanol. Within the ethanol concentration range of 10% to 40%, 20% to 30% ethanol concentration can simultaneously meet the industrial requirements of purity ≥90% and recovery rate ≥87%. 10% and 40% are at the critical values, with purity just reaching the threshold. Elution with 20% to 30% ethanol is the optimal condition. Achieving this precise elution window requires pre-treatment with low-temperature water precipitation for deep impurity removal. Using macroporous resin alone cannot achieve this balance between purity and yield; the combination of the two yields unexpected synergistic effects.

[0058] Experimental Example 3: Hepatoprotective Activity Test Test sample: The high-purity swertiamarin extract prepared in Example 1 of this invention was analyzed by HPLC and the purity of swertiamarin was 92.63%.

[0059] Experimental Methods: Healthy SPF-grade SD rats were randomly divided into a blank control group, a CCl4 model group, a biphenyl diester positive control group, and low-dose, medium-dose, and high-dose swertiamarin groups. Each group was administered the drug once daily by gavage, while the blank control and model groups received an equal volume of physiological saline. The administration was repeated for 7 days. One hour after the last administration, except for the blank control group, rats were intraperitoneally injected with carbon tetrachloride-vegetable oil solution to induce acute chemical liver injury. The blank control group received an equal volume of pure vegetable oil intraperitoneally. After modeling, rats were fasted but allowed free access to water for 16 hours. Blood was collected from the orbital venous plexus, and serum was separated to detect the activities of alanine aminotransferase (ALT) and aspartate aminotransferase (AST).

[0060] Experimental results: The results are as follows Figure 3As shown, compared with the blank control group, the serum ALT and AST levels in the CCl4 model group rats were significantly increased, and the acute liver injury model was successfully established. Compared with the model group, the medium and high dose groups of swertiamarin significantly reduced the abnormally elevated serum ALT and AST levels, and the hepatoprotective effect showed a clear dose-dependent effect.

[0061] Experimental conclusion: The high-purity swertiamarin extract prepared by this process has a definite protective effect against carbon tetrachloride-induced chemical acute liver injury, and can be used to prepare hepatoprotective drugs and health care products, providing pharmacodynamic experimental support for the pharmaceutical use of this application.

[0062] Experiment Example 4: In vitro anti-inflammatory activity assay of LPS-induced RAW264.7 macrophages Test sample: The high-purity swertiamarin extract prepared in Example 1 of this invention was analyzed by HPLC and the purity of swertiamarin was 92.63%.

[0063] Experimental Methods: Mouse mononuclear macrophages (RAW264.7) were used to verify their in vitro anti-inflammatory activity. Six groups were set up: a blank control group, an LPS inflammation model group, a dexamethasone positive control group, and low-concentration, medium-concentration, and high-concentration swertiamarin groups. First, a CCK-8 cytotoxicity pre-test was used to screen for non-cytotoxic gradient drug concentrations. After cell culture was stabilized, cells were pretreated with different concentrations of swertiamarin for 2 h. Except for the blank control group, all other groups received an equal volume of LPS solution to induce cellular inflammation. The blank control group received an equal volume of cell culture medium, and the positive control group received dexamethasone simultaneously. After stimulation, the cell supernatant was collected, and the levels of pro-inflammatory factors TNF-α and IL-6 in the supernatant were detected using an ELISA kit.

[0064] Test results: such as Figure 4 As shown, compared with the blank control group, the levels of TNF-α and IL-6 in the cell supernatant of the LPS model group were significantly increased, indicating that the in vitro inflammation model was successfully established. Compared with the model group, dexamethasone positive control significantly inhibited the release of the two pro-inflammatory factors; the low concentration group of swertiamarin had a weak inhibitory effect on inflammatory factors, while the medium and high concentration groups reduced the secretion levels of TNF-α and IL-6 in a dose-dependent manner, and the in vitro anti-inflammatory inhibitory effect of the high concentration group was similar to that of the positive control dexamethasone.

[0065] Experimental conclusion: The high-purity Swertia japonica extract prepared by this process can significantly inhibit the release of pro-inflammatory factors from macrophages induced by LPS, and its in vitro anti-inflammatory activity is definite, providing in vitro cellular pharmacodynamic experimental support for the anti-inflammatory pharmaceutical use of this application.

[0066] In summary, the high-purity swertiamarin extraction and purification process provided by this invention uses low-temperature water precipitation at 0-10℃ to deeply remove lipid-soluble impurities as the core pre-step, combined with precise fractional elution with 20%-30% ethanol. This breaks the technical prejudice in the field that "macroporous resins are only suitable for crude enrichment and must be superimposed with silica gel column chromatography or recrystallization to obtain high-purity products." Deep purification from crude extract to a product with a purity ≥90% can be completed in a single step using macroporous adsorption resin. This process features mild conditions, controllable parameters, and good reproducibility throughout, effectively avoiding the degradation risk of heat-sensitive iridoid glycosides, significantly reducing organic solvent consumption and production costs. It solves the technical challenge of balancing purity, yield, and cost in the industrial production of high-purity swertiamarin, making it suitable for large-scale standardized production.

[0067] This specific embodiment is merely an explanation of this application and is not intended to limit it. After reading this specification, those skilled in the art can make modifications to this embodiment without contributing any inventive step, but such modifications are protected by patent law as long as they fall within the scope of the claims of this application.

Claims

1. A process for extracting and purifying high-purity swertiamarin, characterized in that, It includes: S1. Take the dried whole medicinal herb, roughly cut it into segments, add 55%~85% ethanol aqueous solution (by volume) and heat under reflux to extract 2~3 times. Combine the extracts and filter. Concentrate the filtrate under reduced pressure at 45~60℃ to an alcohol extract with a relative density of 1.01~1.1 at 50℃. S2. Add purified water to the alcohol extract to dilute and stir evenly. Let it stand at 0~10℃ for 8~24h to allow fat-soluble impurities to settle. Then centrifuge for 8~15min, collect the supernatant and concentrate under reduced pressure. S3. The obtained concentrated solution is loaded onto a macroporous adsorption resin column. The macroporous adsorption resin is a non-polar macroporous adsorption resin. The loading flow rate is 0.5~2 BV / h. After loading, it is eluted with 1~5 BV of pure water and then with 2~8 BV of 10%~40% ethanol aqueous solution. The target eluent is collected, concentrated under reduced pressure at 40~55℃, and then dried under low temperature vacuum to obtain Swertia japonica extract. The extract contains ≥90% swertiamarin, ≤1.2% gentiopicrin, and ≤0.8% gentiopicrin.

2. The extraction and purification process according to claim 1, characterized in that, In step S1, the material-to-liquid ratio for the heating and reflux extraction is 1g:8~15mL, and the extraction time is 1~2h each time.

3. The extraction and purification process according to claim 1, characterized in that, In step S2, the mass ratio of the alcohol extract to purified water is 1:2~6.

4. The extraction and purification process according to claim 1, characterized in that, In step S1, the volume fraction of the ethanol aqueous solution is 60%~80%, and the relative density of the alcohol extract measured at 50°C is 1.03~1.

1.

5. The extraction and purification process according to claim 1, characterized in that, In step S3, the macroporous adsorption resin is selected from any one of D101, AB-8, or LX-183S.

6. The extraction and purification process according to claim 1, characterized in that, In step S3, the sample loading flow rate is 0.5 BV / h, the elution volume of pure water is 2~4 BV, the volume fraction of the target eluent is 20%~30%, and the elution volume is 2~6 BV.

7. The extraction and purification process according to claim 1, characterized in that, In step S1, the heating and reflux extraction is performed 3 times, with each extraction lasting 1 hour.

8. A high-purity swertiamarin extract, characterized in that, It is prepared by the extraction and purification process described in any one of claims 1 to 7.

9. The high-purity swertiamarin extract according to claim 8, characterized in that, The extract contains ≥90% swertiamarin, ≤1.2% gentiopicrin, ≤0.8% gentiopicrin, and <0.5% total fat-soluble impurities.

10. The use of the high-purity Swertia japonica extract as described in claim 8 in the preparation of drugs for treating type II diabetes, anti-anxiety, and antidepressant diseases.